Phase II study of gemcitabine, bevacizumab and erlotinib in locally advanced and metastatic pancreatic cancer.

Trial Profile

Phase II study of gemcitabine, bevacizumab and erlotinib in locally advanced and metastatic pancreatic cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Apr 2012 Actual patient number changed from 30 to 32 as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top